German medtech startup RAYDIAX has secured €7.5 million in funding to advance clinical trials and prepare the market entry of its therapy assistance CT system, TACT.
The financing includes €5 million in venture capital from existing business angels, bmp Ventures through the IBG funds, and a new investment from the GETEC Family Office of Dr. Karl Gerhold. An additional €2.5 million was awarded through the European Commission’s EIC Accelerator program.
Moving Toward First Clinical Applications
The new capital will support first-in-human studies of the TACT system, which are designed to generate early clinical evidence for the technology. At the same time, RAYDIAX plans to further develop the system toward production readiness while building internal structures for sales, manufacturing, and quality management.
These steps are intended to prepare the company for the first commercial installations of its imaging system.
RAYDIAX was founded as a spin-off from the STIMULATE research campus at Otto von Guericke University Magdeburg. The company focuses on developing imaging technologies specifically designed for minimally invasive medical procedures.
Advertisement
A Dedicated CT System For Interventional Oncology
The TACT system is designed as a therapy assistance CT scanner optimized for minimally invasive cancer treatments. It supports clinicians during therapy planning, execution, and monitoring within a single integrated imaging platform.
Minimally invasive treatments are becoming increasingly important as cancer incidence rises and healthcare systems face growing pressure from aging populations. Compared with traditional surgical procedures, these therapies can often reduce recovery times, lower complication risks, and shorten hospital stays.
By enabling more efficient and precise imaging during interventions, RAYDIAX aims to expand the range and accessibility of minimally invasive cancer therapies.
European Support For DeepTech Innovation
The funding from the European Union’s EIC Accelerator program highlights the strategic importance of the technology within Europe’s deeptech ecosystem. The program supports companies developing high-impact innovations with strong scaling potential.
Alongside venture investment, the grant funding will help RAYDIAX progress through clinical validation and regulatory preparation while strengthening its organizational infrastructure for market expansion.
From Research Lab To Commercial Deployment
The company’s roots lie in the STIMULATE research campus, a collaboration between academic institutions, healthcare providers, and industry partners focused on image-guided minimally invasive therapies.
This research environment has supported the development of the TACT technology, enabling RAYDIAX to transition from laboratory innovation to clinical application.
With clinical trials approaching and market preparations underway, the company aims to establish a new category of imaging systems dedicated to interventional oncology.
About RAYDIAX
Founded in 2022 and headquartered in Magdeburg, RAYDIAX develops advanced computed tomography technologies designed for minimally invasive image-guided therapies. The company emerged from the STIMULATE research campus and Otto von Guericke University Magdeburg, combining hardware and software innovation to improve cancer treatment workflows and patient outcomes.
